Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JBI-802 alone or with pembrolizumab in STK11-mutated NSCLC
NCT07207395Phase 2Recruiting
- Sponsor
- The Christ Hospital
- Start
- Apr 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JBI-802 in non-small cell lung cancer (NSCLC), sponsored by The Christ Hospital. Started Apr 2025; status: recruiting.
02
Drugs
JBI-802
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07207395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07207395.